01—Abstract
Summary
Summary of the 10-K filed February 22, 2018. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation's 2017 Form 10-K reports net sales of $2,287,312 thousanda ($2.29 billion), up 8% from $2,113,043 thousand in 2016, with organic sales up 6% and acquisitions/divestitures adding 2%.
Operating income rose 22% to $502,556 thousandb, and operating margin was 22.0%, up 250 basis points. Net income increased 24% to $337,257 thousand, and diluted EPS was $4.36, compared with $3.53 in 2016. Adjusted EPS, which excludes restructuring, divestiture gains and losses, and a 2016 pension settlement, was $4.31, up from $3.75.
Adjusted EBITDA was $583,560 thousandc, flat with 2016 in margin terms at 25.5%. The company operates three reportable segments: Fluid & Metering Technologies (38% of 2017 sales), Health & Science Technologies (36%), and Fire & Safety/Diversified Products (26%). Roughly 49% of 2017 sales were to customers outside the U.S. Cash flow from operations was $432.8 million, and capital expenditures were $43.9 million.
Total borrowings declined to $862.2 milliond from $1,020.9 million, and shareholders' equity rose to $1,886.5 million. Management projects approximately 5% organic revenue growth and full-year 2018 EPS of $4.90 to $5.10.
The 2017 results include a $9.3 million gain on the Faure Herman divestiture, $8.5 million of restructuring expense, and a provisional net $0.1 million tax benefit from the Tax Cuts and Jobs Act, which included a $30.3 million transition tax expense and a $40.6 million deferred tax benefit. Goodwill and intangibles totaled $1,704.2 million and $414.7 million, respectively, against $3,399.6 million of total assets.
02—Key points
Key Highlights
- Net sales of $2.29 billion, up 8%, with organic growth of 6% and acquisitions/divestitures adding 2%
- Operating income of $502.6 million, up 22%; operating margin of 22.0%, up 250 basis points
- Diluted EPS of $4.36, up from $3.53; adjusted EPS of $4.31, up from $3.75
- Cash flow from operations of $432.8 million; cash and equivalents of $376.0 million at year-end
- Total borrowings reduced to $862.2 million from $1,020.9 million; shareholders' equity rose to $1,886.5 million
- 2018 outlook: approximately 5% organic revenue growth and full-year EPS of $4.90 to $5.10
- Tax Cuts and Jobs Act produced a net $0.1 million provisional tax benefit, comprising a $40.6 million deferred tax benefit and $30.3 million transition tax expense
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2017, Idex kept $0.15.
- Revenue$2.29B100.0%
- Cost of revenue−$1.26B55.1%
- Gross profit$1.03B44.9%
- Operating costs−$524.1M22.9%
- Operating income$502.6M22.0%
- Interest, other & tax−$165.3M7.2%
- Net income$337.3M14.7%
04—Financials
Financial Highlights
Figures from 10-KFY2017filed February 22, 2018Financial Statements
FY2017 against FY2016
| Line item | FY2017FY2016 | Change |
|---|---|---|
| Revenue | $2.29B$2.11B | +8.2% |
| Cost of Revenue | $1.26B$1.18B | +6.6% |
| Gross Profit | $1.03B$930.77M | +10.3% |
| R&D Expenses | $42.40M$39.40M | +7.6% |
| SG&A Expenses | $524.94M$492.40M | +6.6% |
| Operating Income | $502.56M$412.40M | +21.9% |
| Interest Expense | $44.89M$45.62M | −1.6% |
| Net Income | $337.26M$271.11M | +24.4% |
| EPS (Basic) | $4.41$3.57 | +23.5% |
| EPS (Diluted) | $4.36$3.53 | +23.5% |
| Shares Outstanding (Basic) | 76.23M75.80M | +0.6% |
| Shares Outstanding (Diluted) | 77.33M76.76M | +0.7% |
05—Questions
Frequently Asked Questions
What drove the increase in operating income in 2017?
Operating income rose to $502.6 million from $412.4 million, primarily due to a $9.3 million gain on the Faure Herman divestiture compared with a $22.3 million net loss on four divestitures in 2016, higher sales volume, and the absence of $14.7 million of inventory step-up charges from 2016 acquisitions. These gains were partially offset by higher restructuring costs and higher SG&A from variable and share-based compensation.
How concentrated is IDEX's customer base and where are its sales generated?
No customer accounted for more than two percent of 2017 net sales. Sales were 51% domestic and 49% international, with the Health & Science Technologies segment deriving about 55% of its sales outside the U.S.
What is the company's acquisition strategy and balance sheet exposure?
IDEX pursues acquisitions as a core growth strategy. In 2017 it acquired thinXXS for $38.2 million in cash plus $1.2 million of assumed debt. Goodwill of $1,704.2 million and intangible assets of $414.7 million together represent a significant portion of total assets, creating impairment risk if performance falls short of forecasts.
What are the key financing arrangements and covenants?
Total borrowings were $862.2 million at December 31, 2017, including $750 million of fixed-rate senior notes and $10.7 million drawn on a $700 million revolving facility expiring in June 2020. The company was in compliance with its covenants, with an interest coverage ratio of 13.64 to 1 against a 3.0 to 1 minimum and a leverage ratio of 1.45 to 1 against a 3.50 to 1 maximum.
How did the Tax Act affect IDEX's 2017 results?
The company recorded a net $0.1 million tax benefit, which combined a $40.6 million provisional deferred tax benefit from remeasuring deferred tax balances, $30.3 million of provisional transition tax expense on deemed repatriated foreign earnings, and $10.2 million of additional expense from removing permanent reinvestment assertions for certain subsidiaries. The company expects to finalize these amounts during 2018.
06—Continue